医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Seoul Semiconductor Expands Its Business Through SunLike Natural Sunlight Spectrum LED Technology Patents and Business Rights Transfer

2021年09月01日 AM11:45
このエントリーをはてなブックマークに追加


 

ANSAN, South Korea

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it expects to expand its business of SunLike natural sunlight spectrum LED technology optimized for natural human biological rhythm which has 24-hour cycle, as the transfer of patent rights and business rights of SunLike LED technology has been completed from Toshiba Materials Co., Ltd. (CEO Katsuaki Aoki, Yokohama), which has jointly developed SunLike technology. The global LED lighting sales market is estimated at USD 5 billion as of now.

Seoul Semiconductor and Toshiba Materials were jointly involved in the development and release of SunLike in 2017, which has needed investment to further expand stable production and sales. As a result of continuous consultations between the two companies over the past two years to improve the speed of decision and operational efficiency for the SunLike business, Seoul Semiconductor has acquired all technologies, patents, trademarks, etc. related to SunLike, the light most similar to sunlight. Key workers from Toshiba Materials also joined Seoul Semiconductor, and they will begin efforts to expand sales from September.

SunLike is a LED technology that reproduces the sunlight spectrum (all natural colors such as red, orange, yellow, blue and navy) curve. This is a new conceptual light source optimized for human circadian rhythm by implementing the same wavelength as natural light. Human daily cycle (Body Clock) and solar cycle (24-hour cycle) are different. The sunlight initializes the start of the day to reset the human body’s daily rhythm, allowing for a good health, sleep, and memory.

The 2017 Nobel Prize in Physiology or Medicine was also awarded to three PhDs who identified circadian rhythms. While the spectrum of products that many lighting companies promote as Human Centric Light, or HCL, is simply lowering the blue light peak, SunLike implements the light closest to the sunlight spectrum. Seoul Semiconductor has conducted memory and learning comparison experiments in the U.S, Europe and Korea and myopia prevention experiments in Singapore, with regard to the use of lighting with SunLike technology for the last three years, and will announce the results in October 2021 and CES 2022 exhibition.

“It is important to select natural light that has been optimized for human DNA for millions of years, not brightness and low price anymore. With SunLike technology, Seoul Semiconductor believe that the technology supports to reduce myopia and helps people fall a sleep well at night when cells are regenerated. Also, by returning the sunlight of nature to mankind, we will become the protagonists of a new history of light,” said Chung Hoon Lee, CEO of Seoul Semiconductor.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210831006074/en/

CONTACT

Seoul Semiconductor Co., Ltd.

Jeonghee Kim

Tel: +82-70-4391-8311

Email: jeonghee.kim@seoulsemicon.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™